Evidence map›Paper›PMID 26801201›Full record

ArticlePigment cell & melanoma research2016

Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression.

Sun-Hee Kim, Yuuri Hashimoto, Sung-Nam Cho, Jason Roszik, Denái R Milton, Fulya Dal, Sangwon F Kim, David G Menter, Peiying Yang, Suhendan Ekmekcioglu and 1 more

Open access · greenAbstract read
In one paragraph

Article in Pigment cell & melanoma research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Life Factors and Melanoma: From the Macroscopic State to the Molecular Mechanism.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  3. Regulatory Effect of PGEBiomolecules · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Phytochemical Constituents and Derivatives ofInternational journal of molecular sciences · 2023
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. PTGES/PGEOncogene · 2020
    Article
  13. Article
  14. The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Article
  15. Article
  16. The role of nitric oxide in melanoma.Biochimica et biophysica acta. Reviews on cancer · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Sun-Hee KimDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yuuri HashimotoDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sung-Nam ChoDepartment of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jason RoszikDepartment of Melanoma Medical Oncology and Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Denái R MiltonDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fulya DalDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sangwon F KimDepartment of Psychiatry, Center for Neurobiology and Behavior, Perlman School of Medicine at University of Pennsylvania at University of Pennsylvania, Philadelphia, PA, USA.
David G MenterDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Peiying YangDepartment of General Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Suhendan EkmekciogluDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elizabeth A GrimmDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
UT M.D. Anderson Cancer Center SPORE in MelanomaP50CA093459 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GRIMM, ELIZABETH A · 2004 to 2014
$23.7M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA093459
6 · The paper itself

Abstract

COX-2 and its product PGE2 enhance carcinogenesis and tumor progression, which has been previously reported in melanoma. As most COX inhibitors cause much toxicity, the downstream microsomal PGE2 synthase-1 (mPGES1) is a consideration for targeting. Human melanoma TMAs were employed for testing mPGES1 protein staining intensity and percentage levels, and both increased with clinical stage; employing a different Stage III TMA, mPGES1 intensity (not percentage) associated with reduced patient survival. Our results further show that iNOS was also highly expressed in melanoma tissues with high mPGES1 levels, and iNOS-mediated NO promoted mPGES1 expression and PGE2 production. An mPGES1-specific inhibitor (CAY10526) as well as siRNA attenuated cell survival and increased apoptosis. CAY10526 significantly suppressed tumor growth and increased apoptosis in melanoma xenografts. Our findings support the value of a prognostic and predictive role for mPGES1, and suggest targeting this molecule in the PGE2 pathway as another avenue toward improving melanoma therapy.

Indexed as

Disease ProgressionAnimalsCell Line, TumorCell SurvivalDinoprostoneDisease-Free SurvivalGene Expression Regulation, NeoplasticHumansMelanomaMice, NudeMicrosomesMiddle AgedNitric Oxide DonorsNitric Oxide Synthase Type IIProstaglandin-E SynthasesSignal TransductionDinoprostoneNitric Oxide DonorsNitric Oxide Synthase Type IIProstaglandin-E Synthasescell survivalinducible nitric oxide synthaseinflammationmelanomamicrosomal PGE2 synthase-1prostaglandin E2

Identifiers

PMID26801201
PMCPMC4840087
OpenAlexW2301440856

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.